Literature-reported formulation composition
Component: Trp-L1-T4 | Reported molar ratio: 25 | Role: Ionizable lipid
sales@dcchemicals.com
Lipid Trp-L1-T4
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: Cholesterol | Reported molar ratio: 20 | Role: Sterol
Literature-reported formulation composition
Component: DMG-PEG2000 | Reported molar ratio: 0.5 | Role: PEG lipid
Literature-reported formulation composition
Component: DOPE | Reported molar ratio: 10 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Reported ratio sum | Reported molar ratio: 55.5 | Role: Original ratio retained
Reported observation
Literature-reported GFP-positive primary Tfh cells 59.8% 24 h after 80 ng GFP-saRNA per 50,000 cells · Selected as the lead dose with minimal cytotoxicity Main text, printed p. 592 / PDF p. 5; Supplementary Figure S1H,I
Reported observation
Literature-reported Hydrodynamic diameter 107.0 ± 13.4 nm Post-formulation characterization · UFC-TLNP Supplementary Table S2, SI PDF p. 12
Reported observation
Literature-reported Polydispersity index 0.16 ± 0.05 Post-formulation characterization · UFC-TLNP Supplementary Table S2, SI PDF p. 12
Reported observation
Literature-reported Zeta potential -1.9 ± 1.5 mV Post-formulation characterization · UFC-TLNP Supplementary Table S2, SI PDF p. 12
Reported observation
Literature-reported saRNA encapsulation efficiency 85.28 ± 3.56% Post-formulation characterization · UFC-TLNP Supplementary Table S2, SI PDF p. 12
Reported observation
CAR and Foxp3 coexpression UFC-TLNP produced a reported 59.0% CAR-positive and Foxp3-positive Tfh-cell population. Tfh cells; UFC-saRNA; in vitro · Main Figure 2B, PDF p. 4
Reported observation
Targeted regulatory-phenotype persistence After UFC-RLNP treatment, the reported Foxp3-positive Tfh fractions were 60.6% on day 1, 56.4% on day 3, 51.9% on day 7 and 49.2% on day 14. CXCR5-antibody-functionalized RLNP; n=3; in vitro · Main Figure 3B,C, PDF p. 6
Reported observation
Tfh versus conventional T-cell expression At 24 h, UFC-RLNP produced 61.3% DeltaLNGFR-positive Tfh cells versus 1.44% conventional T cells in the reported assay. Tfh-restricted UFC-saRNA translation plus CXCR5-targeted uptake; n=3 · Main Figure 3I,J
Reported observation
Preclinical autoimmune-hepatitis study A single UFC-Tw/RLNP dose improved reported biochemical, immune and liver-histology endpoints in both prophylactic and established Ad-2D6 autoimmune-hepatitis-II mouse experiments relative to saline controls. Female C57BL/6J mice; 5 micrograms saRNA IV on day 1 or day 28; preclinical evidence only · Main Figures 6-7 and Supplementary Figures S6-S7
Reported observation
Reported experimental tolerability The authors reported no detectable red-blood-cell lysis in the tested assay, no significant Tfh cytotoxicity at tested in vitro doses, stable body weight and no treatment-associated abnormality in examined major-organ H&E sections. Assay- and mouse-study-specific observations; not a formal toxicology program · Main Figure 2M; Supplementary Figures S1, S2G, S6A and S7G